Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia.
Giraldo-Ocampo S et al.
Medicine, 2023
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2022
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
PharmVar GeneFocus: CYP2C9.
Sangkuhl K et al.
Clinical Pharmacology and Therapeutics, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Correction to "Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19".
Unknown Author
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Metabolism of 7-ethoxycoumarin, flavanone and steroids by cytochrome P450 2C9 variants.
Uno T et al.
Biopharmaceutics & Drug Disposition, 2017
Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.
Hiratsuka M
Biological & Pharmaceutical Bulletin, 2016
Functional characterization of 32 CYP2C9 allelic variants.
Niinuma Y et al.
The Pharmacogenomics Journal, 2014
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
Genetic and clinical factors relating to warfarin dosing.
Jonas DE et al.
Trends in Pharmacological Sciences, 2009
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
Agúndez JA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2009
Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.
Limdi N et al.
Personalized Medicine, 2007
Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.
Daly AK et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.
García-Martín E et al.
Molecular Diagnosis & Therapy, 2006
The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview.
Ferraro TN et al.
Epilepsy & Behavior : E&b, 2005
Discovery of new potentially defective alleles of human CYP2C9.
Blaisdell J et al.
Pharmacogenetics, 2004